MINI-REVIEW

DNA Methylation Biomarkers for Nasopharyngeal Carcinoma: Diagnostic and Prognostic Tools

Wei Jiang*, Rui Cai, Qiu-Qiu Chen

Abstract

Nasopharyngeal carcinoma (NPC) is a common tumor in southern China and south-eastern Asia. Effective strategies for the prevention or screening of NPC are limited. Exploring effective biomarkers for the early diagnosis and prognosis of NPC continues to be a rigorous challenge. Evidence is accumulating that DNA methylation alterations are involved in the initiation and progression of NPC. Over the past few decades, aberrant DNA methylation in single or multiple tumor suppressor genes (TSGs) in various biologic samples have been described in NPC, which potentially represents useful biomarkers. Recently, large-scale DNA methylation analysis by genome-wide methylation platform provides a new way to identify candidate DNA methylated markers of NPC. This review summarizes the published research on the diagnostic and prognostic potential biomarkers of DNA methylation for NPC and discusses the current knowledge on DNA methylation as a biomarker for the early detection and monitoring of progression of NPC.

Keywords: DNA methylation - nasopharyngeal carcinoma - biomarker - diagnosis - prognosis

Asian Pac J Cancer Prev, 16 (18), 8059-8065

Introduction

Nasopharyngeal carcinoma (NPC) is one of the most prevalent malignancies in southern China and southeastern Asia. In southern China, the incidence rate is about 25-50 per 100,000 person years (Jeannel et al., 1999; McDermott et al., 2001; Wei and Sham, 2005). Despite considerable advances in NPC treatment, local recurrence or distant metastasis is observed frequently. The main challenge of NPC management remains a lack of effective biomarkers for developing more precise diagnostic, prognostic, treatment and prevention approaches (Heng et al., 1999; Hong et al., 2000; Ayan et al., 2003).

To date, abundant evidence convincingly demonstrated that aberrant epigenetic silencing of many tumor suppressor genes (TSGs), cellular functional genes and micro-RNAs (miRNAs) affect the normal cell growth and development (Esteller, 2007; Lujambio et al., 2008), which leads to various human malignancies (Belinsky et al., 1998; Mittag et al., 2006), that has been recognized as a common and early event in human cancers(Jones, 1996; Baylin and Herman, 2000). Of particular interest, the patterns of DNA methylation of normal tissues are distinct from those of tumor tissues, DNA methylation as a potential biomarker for diagnosis, prognosis, personalized therapy and disease management is just beginning to emerge. Recently, investigators have employed specific sets of methylated genes served as biomarkers for clinical practice in several types of cancer, such as lung (Koga et al., 2011), melanoma (You et al., 2010), and breast (Ramos et al., 2010).

Like other types of cancers, NPC is associated with multiple genetic mutations and epigenetic aberrations (Lo and Huang, 2002; Lo et al., 2004). Studies have suggested that aberrant DNA methylation at the promoter CpG islands underlie the development and progression of NPC (Tao and Chan, 2007; Razak et al., 2010). In addition, growing evidence demonstrates that many genes are predominantly silenced by DNA methylation in NPC epithelial cells (Li et al., 2011a; Bruce et al., 2015). Identification of differential DNA methylation genes could contribute to the understanding of pathogenetic mechanisms and develop the available biomarkers to diagnose NPC early and optimize and personalize treatment for NPC.

Here, we detail the the current knowledge of DNA methylation biomarkers in terms of the diagnosis and prognosis of NPC.

Overview of research on DNA methylation and NPC

Over the past decade, many studies have specifically explored DNA methylation in NPC, and a large variety of genes with aberrant methylation (including the different pathways involved in carcinogenesis) have been reported

Earlier studies specifically assessed DNA methylation as either "present" or "absent" in a single gene or multiple genes. For instance, Lo and colleagues (Lo et al., 2002) reported that hypermethylation of a single gene *EDNRB* was detected in 19/21 (90.5%) primary tumors, whereas no methylation was found in normal nasopharyngeal

Department of Radiation Oncology, the Affiliated Hospital of Guilin Medical University, Guilin, China *For correspondence: weijiang@glmc.edu.cn

Wei Jiang et al

epithelia. Liu and colleagues (Liu et al., 2003) revealed that the BLU promoter region occured hypermethyaltion in 74% of primary NPC tumors, whereas non-neoplastic nasopharyngeal tissue exhibited low rmethylation. From multiple-gene studies, Kwong and colleagues (Kwong et al., 2002) detected the prevalence of several genes methylation in NPC tumors including RARbeta2 (80%), DAP-kinase (76%), p16 (46%), p15 (17%), p14 (20%), and MGMT (20%), respectively. More recently, Yanatatsaneejit P and colleagues (Yanatatsaneejit et al., 2008) examined the methylation status of eight genes and higher frequencies of CCNA1 (48%), RARRES1 (51%), and HRASLS (17%), respectively, were found in NPC tumors. Significant differences among numerous the studied DNA methyaltion were scored both in the NPC and control tissues.

Detailed mechanistic studies that further elucidated biologic roles in NPC suggested that transcriptional inactivation of different TSGs by promoter hypermethylation is associated with many important cellular processes involved in tumorigenesis. Several reports have provided convincing evidence that UCHL1, WIF1, RASSF1A, FEZF2, LOX, Kank1 and RRAD are frequently inactivated by promoter methylation in NPC (Chow et al., 2004; Lin et al., 2006; Li et al., 2010; Mo et al., 2012; Shu et al., 2013; Sung et al., 2014; Luo et al., 2015). Restoration of the expression of these genes after demethylation always suppressed NPC cell growth, colony formation and apoptosis of NPC cells, as well as inhibiting their migration and invasion. Similarly to TSGs, silencing of miRNA by hypermethyaltion in NPC has shown its important involvement in various factors during carcinogenesis. For instance, restorations of miR-148a, miR31, miR34c and miR24 expressions inhibit cell growth and migration in NPC cells by targeting different downstream genes (Cheung et al., 2014; Li et al., 2014a; Wang et al., 2014; Li et al., 2015b).

In addition, DNA methyaltion of TSGs were found to involved in multiple biological pathways during carcinogenesis and progression. It was recently reported that hypermethylated gene ADAMTS8 plays a promoting role in NPC progression by triggering EGFR-MEK-ERK signaling (Choi et al., 2014) Similarly, highly methylated gene ROR2 participated in the negative regulation of cell functions through suppressing β -catenin and AKT pathway (Li et al., 2014c). Tao and colleagues also revealed that gene methylation disrupts Wnt signaling, MAPK signaling, regulation of the actin cytoskeleton, Hedgehog signaling and TGF- β signaling pathways in NPC using microarray screening methods (Li et al., 2015a).

Analyses of DNA methylation not only provides the opportunity for understanding the molecular pathogenesis of the disease but can also be used to develop new potential new markers for diagnosis, prognosis and prediction of NPC.

DNA methylation as a potential diagnostic and prognostic markers of NPC

Due to the early occurrence and stability of DNA methylation, analysis of DNA methylation status has been suggested as a useful markers for the early detection and for prediction of outcome of multiple types of cancer (Delpu et al., 2013). DNA methylation is strongly associated with NPC, and hypermethylated DNA has great potential to become a biomarker for the early detection and prognosis of NPC. (Figure 1)

Marks for NPC Diagnosis

In 1996, Lo et al.(Lo et al., 1996) firstly reported high methylation level of p16 in NPC xenograft, cell line



Figure 1. DNA Methylation Can Potentially Serve as a Bomarker for the Early Detection and Prognosis of Nasopharyngeal Carcinoma (NPC). NP: nasopharyngeal; M&T: mouth and throat; MSP: methylation-specific polymerase chain reaction; MS-HRM: methylation-sensitive high-resolution melting.

p16 NPC primery tumor biopsiss MSP 22:06:9 dagaosis Agadi et al., 2003; (Challon et al., 2003) MAX Training fluid 17:6	Biomarker	Type of Sample	Method	Range of Methylation frequency	Marker Function	Reference
NP bendame 44.00% 201:: Ital and 201:: 001: Max Taniang find 17.5 (Chang et al. 2003) Max Signal 17.5 (Chang et al. 2003) Max Taniang find 17.5 (Chang et al. 2003) Max Taniang find MSP 35.6 Max Taniang find S0.006 (Chang et al. 2002) Max Taniang find 50.006 (Chang et al. 2003) Max Taniang find 50.006 (Chang et al. 2004) Max Taniang find 50.006 (Chang et al. 2004) Max Taniang find 50.006 (Chang et al. 2004) Max Taniang find 50.006 (Chang et al. 2003) Max Taniang find 50.606 (Chang et al. 2	p16	NPC primary tumor biopsies	MSP	23-66%	diagnosis	(Ayadi et al., 2008; Challouf et al.,
NP seeks 1172 (Chang et al. 2003) MAXSPI A 1725 (Chang et al. 2003) MASSPI A 1725 (Chang et al. 2003) MASSPI A 1725 (Chang et al. 2003) MASSPI A 1725 (Chang et al. 2003) MAX Trenser fluid 1725 (Chang et al. 2003) MAX Trenser fluid 1726 (Chang et al. 2004) CDHI MCX Trenser fluid 1726 (Chang et al. 2004) MAX Trenser fluid 1726 (Chang et al. 2004) CCHI Incs 1007 (Chang et al. 2004) MAX Trenser fluid		NP brushing		46.40%		2012; Tian et al., 2013) (Tong et al., 2002)
Markan Markan Markan Markan Markan Markan Markan AASSELLA Kreinarts (unor biopries) MSP 30.537 diagnosis (Vong et al., 2003) (Vong et al., 2003) DAP-Linne MC primary (unor biopries) MSP 77.56 diagnosis (Vong et al., 2003) CDPL MC primary (unor biopries) MSP 77.56 diagnosis (Vong et al., 2003) CDPL MSP 77.56 diagnosis (Vong et al., 2003) (Vong et al., 2003) Construction MSP 75.56 67.66 diagnosis (Vong et al., 2003) Construction MSP 75.56 67.66 diagnosis (Vong et al., 2003) Construction MSP 77.57 diagnosis (Vong et al., 2003) (Vong et al., 2003) Construction MSP 77.57 diagnosis (Vong et al., 2003) (Vong et al., 2003) MSP results 77.57 diagnosis (Vong et al., 2003) (Vong et al., 2003) MSP results 77.57 diagnosis		NP swabs		17%		(Chang et al., 2003b) Chang et al., 2003b)
RASSFIA N/C primary numor biopsies MSP 46.77% diagnosis (Chang et al., 2003) (Tong et al., 2004) Met Transm final 77% 77% diagnosis (Tong et al., 2002) (Yong et al., 2003) (Yong et al., 2004) (Yong et al., 2005) (Yong et al.,		Plasma		42%		(Wong et al., 2003b)
MP evalue D-326 Comparison DAP-Linux MSP 756-75 diagnosis (Wong et al., 2002) (Long et al., 2003)) MPC cell lines S00-65 Giagnosis (Wong et al., 2004) MAT runs giad S00-65 Giagnosis (Wong et al., 2004) MAT runs giad S00-65 Giagnosis (Wong et al., 2004) CDH1 Harran MSP 326 Giagnosis (Wong et al., 2004) CDH1 Harran MSP 326 Giagnosis (Wong et al., 2003) NPC cell lines NP variab 275 Giagnosis (Wong et al., 2003) (Charg et al., 2003) NPC cell lines 100-6 166 100-6 Giagnosis (Wong et al., 2003) NPC cell lines 100-6 166 100-6 Giagnosis (Wong et al., 2003) NPC cell lines 100-6 Giagnosis (Wong et al., 2003) 100-0 NPC cell lines 100-6 Giagnosis (Wong et al., 2003) 100-0 NPC cell lines 100-0 10-0	RASSF1A	NPC primary tumor biopsies	MSP	46-67%	diagnosis	(Chang et al., 2003b; Wong et al., 2003b) (Tong et al., 2002)
DAP kinase MR 1 missing minuted MR 1 minuted MR 1 minuted MR 1 minuted MR 1 minuted		NP swabs		33%		(1012 et al., 2002)
NPC cell lines in 80% in (Tong et al., 2002) in CDH1 Regensary numer biopsies MSP 20% diagnosis (Wong et al., 2004) CDH1 Regensary numer biopsies MSP 25% 65% diagnosis (Wong et al., 2004) CDH1 Regensary numer biopsies MSP 25% 65% diagnosis (Chang et al., 2004) CDR1 NPC cell lines 100% 17% diagnosis (Chang et al., 2003) NPC cell lines 100% 100% 100% (Chang et al., 2003) NPC cell lines 100% 100% (Chang et al., 2003) NPC cell lines 100% 100% (Chang et al., 2003) NPC cell lines 100% 46% diagnosis (Wong et al., 2003) NPC cell rines MSP 40% diagnosis (Wong et al., 2003) NPC rinnary numer biopises MSP 50.60% diagnosis (Wong et al., 2003) NPC rinnary numer biopises MSP 50.60% diagnosis (Chang et al., 2003) NPC rinnary numer biopises MSP 50.60% diagnosis (Chang et al., 2003) NPC rinnary numer biopises MSP 50.60% diagnosis (Kwong et al., 2003) <t< td=""><td>DAP-kinase</td><td>M&T rinsing fluid NPC primary tumor biopsies</td><td>MSP</td><td>37% 75%-77%</td><td>diagnosis</td><td>(Wong et al., 2002; Chang et al., 2003b)</td></t<>	DAP-kinase	M&T rinsing fluid NPC primary tumor biopsies	MSP	37% 75%-77%	diagnosis	(Wong et al., 2002; Chang et al., 2003b)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		NPC cell lines		80%	0	(Tong et al., 2002)
MAX In many fluid 30% bit is a second		NP swabs		63%		
		M&T rinsing fluid Plasma		50% 20%		(Wong et al., 2004)
E-cadherin NPC primary tumor biopsies MSP 52% e5% diagnosis (Change et al., 2011) NPC cell lines 1006 NPC primary tumor biopsies MSP 17% HIN-1 NPC primary tumor biopsies MSP 24% HIN-1 NPC primary tumor biopsies MSP 50.80% HIN-1 NPC primary tumor biopsies MSP 50.78% HIN-1 Mingenosis (Wong et al., 2003) HIN-1 NPC primary tumor biopsies MSP 50.78% HIN-1 Mingenosis (Wong et al., 2003) HIN-1 NPC primary tumor biopsies MSP 50.78% HIN-1 Mingenosis (Wong et al., 2004) HIN-1 NPC primary tumor biopsies MSP 50.78% HIN-1 Mingenosis (Wong et al., 2005) HIN-1 NPC primary tumor biopsies MSP 50.78% HIN-1 Mingenosis (Wong et al., 2005) HIN-1 NPC primary tumor biopsies MSP 50.78% HIN-1 NPC primary tumor biopsies MSP 50.78% HIN-1 NPC primary tumor biopsies MSP 100% HIN-1 NPC primary tumor biop	CDH1	NPC primary tumor biopsies	MSP	50% 46%	diagnosis	(Wong et al., 2003b) (Wong et al., 2004)
NPC cell lines 100% Ren et al., 2011) HIN-1 MKT rinsing fluid 43% (Chang et al., 2003) MKT rinsing fluid 43% (Chang et al., 2003) masopharynegal synabs 46% (Wong et al., 2003) MKT MKT primary tumor biopsics MSP 46% MKT MKT primary tumor biopsics MSP 26% MKT MKT primary tumor biopsics MSP 26% MKT MKT primary tumor biopsics MSP 26.0% MKT MKT primary tumor biopsics MSP 26.0% MKT MKT primary tumor biopsics MSP 50.0% MKT MKSP 50.4% diagnosis (Wong et al., 2003) MKT MKT primary tumor biopsics MSP 50.6% diagnosis	E-cadherin	NPC primary tumor biopsies	MSP	52% -65%	diagnosis	(Chang et al., 2003b; Tsao et al., 2003;
NP svabs 278 (Chang et al., 2003b) HIN 1 MSP 1004 (Brang et al., 2003b) NPC cell lines 1004 1004 (Brang et al., 2003b) MIN 1 NPC cell lines 1005 (Brang et al., 2003b) MCMT NPC primary tumor biopies MSP 236 MCMT NPC primary tumor biopies MSP 236 MCMT NPC primary tumor biopies MSP 55.60% MCT NPC primary tumor biopies MSP 55.60% MRT NPC primary tumor biopies MSP 55.60% MRT NPC primary tumor biopies MSP 56.60% diagnosis (Wong et al., 2003b) MRT NPC primary tumor biopies MSP 51.60% diagnosis (Wong et al., 2003b) GADDGG NPC primary tumor biopies MSP 51.72% diagnosis (Wong et al., 2003b) GADDGG NPC primary tumor biopies MSP 77% diagnosis (Wong et al., 2005b) GADDGG NPC primary tumor biopies MSP 77% diag		NPC cell lines		100%		Ran et al., 2011) (Ran et al., 2011)
 HIN-1 NPC primary tumor biopsizes mesopharyngel avails in the primary tumor biopsizes provide the primary tumor biopsizes NPC primary tumor biopsizes NPC primary tumor biopsizes MGM1 MCM1 NPC primary tumor biopsizes MGM1 NPC primary tumor biopsizes MSP S50 80% diagnosis (Chang et al., 2003b) (Chang et al., 2003b) (Wong et al., 2003b) (Chang et al., 2003b)		NP swabs		27%		(Chang et al., 2003b) (Chang et al., 2003b)
NPC cell lines 100% MRAW 19% Plasma 18% WG MF NPC cents of peripheral blood 18% MILHI NPC primary tumor biopsize MSP 40% MILHI NPC primary tumor biopsize MSP 50.40% MILHI NPC primary tumor biopsize MSP 50.40% MILHI NPC primary tumor biopsize MSP 50.40% MILHI NPC primary tumor biopsize MSP 50.60% diagnosis (Chang et al., 2003; Hutajulu et al., 2011) MILHI NPC primary tumor biopsize MSP 50.60% diagnosis (Cheng et al., 2005) GADDSG Primary tumor biopsize MSP 50.60% diagnosis (Yong et al., 2005) CHFR NPC primary tumor biopsize MSP 57.87% diagnosis (Yong et al., 2005) DLCI NPC primary tumor biopsize MSP 57.62% diagnosis (Yong et al., 2005) DLCI NPC primary tumor biopsize MSP 57.62% diagnosis (Yong et al., 2006) DPCH	HIN-1	NPC primary tumor biopsies	MSP	43%	diagnosis	(Wong et al., 2003a)
throad-mixing fluids 19% Plasma pright prime MGAT top compary tumor biopsiss MSP MGM top compary tumor biopsiss MSP 40% MGM top compary tumor biopsiss MSP 50 80% MR top compary tumor biopsiss MSP 50 60% diagnosis (Wong et al., 2003b) Wong et al., 2003b) MR top compary tumor biopsiss MSP 50 60% diagnosis (Chang et al., 2003b) Wong et al., 2003b) MR top compary tumor biopsiss MSP 50 60% diagnosis (Ying et al., 2005) GADD450 NC contang tumor biopsiss MSP 77% 700% diagnosis (Ying et al., 2005) CRBP NC contang tumor biopsiss MSP 79% 67.119 diagnosis (Ying et al., 2005) CRBP NC contang tumor biopsiss MSP 79% 67.23 diagnosis (Ying et al., 2005) CRBP NC contang tumor biopsiss MSP 99% 67.23 diagnosis		nasopharyngeal swabs		100% 46%		
hoff of the second peripheral blood second s		throat-rinsing fluids		19% 18%		
MGM1 NEQ primary tumor biopsies MSP 50.89% diagnosis (Wong et al., 2003b) MF prabs tumor biopsies MSP 50.89% diagnosis (Chang et al., 2003b) Wong et al., 2003b) MR Trinsing fluid 40% Plasma and/or brushing MSP 50.90% diagnosis (Chang et al., 2003b) MR Trains and/or brushing MSP 50.90% diagnosis (Chang et al., 2003b) MR C primary tumor biopsies MSP 10.90% diagnosis (Wong et al., 2003b) MR C primary tumor biopsies MSP 01.90% diagnosis (Wong et al., 2005b) CHFR NC primary tumor biopsies MSP 01.90% diagnosis (Wong et al., 2005b) CHFR NC primary tumor biopsies MSP 02.90% diagnosis (Wong et al., 2005b) CHFR NC primary tumor biopsies MSP 02.90% diagnosis (Wong et al., 2005b) CHFR NC primary tumor biopsies MSP 02.90% diagnosis (Wong et al., 2005b) CHFR NC primary tumor biopsies MSP 02.90% diagnosis (Kwong et al., 2005b) CHF NC primary tumor biopsies MSP 02.90% (21/33) CHF NC primary tumor biopsies MSP 02.90% (21/33) CHF NC primary tumor biopsies MSP 80.97% (22/36) diagnosis (Kwong et al., 2006b) NC primary tumor biopsies MSP 100% (21/33) CHF NC primary tumor biopsies MSP 100% (21/33) MSP 1000% (21/33) MSP 1000% (21/33) MSP 1000% (21/33) MR 1000% diagnosis (Liu et al., 2007b) NC primary tumor biopsies MSP 100% (21/33) MR 1000% (21/34) MR 1000% (21/34) MR 1000% (21/34) MR 1000% (21/34) MR 1000% (21/34) MR 1000% (21/34) MR		buffy coats of peripheral blood		46%		
p15 NPC primary tumor biopsies MRT mang fluid MSP 50-80% (35%) diagnosis (Chang et al., 2003b) Wong et al., 2003b) RZI NYC paraffin and/or brushing MSP MSP 50-60% diagnosis (Chang et al., 2003b) THBSI NYC primary tumor biopsise MSP MSP 50-60% diagnosis (Wong et al., 2003b) CHFR NYC primary tumor biopsise MSP MSP 50% (R11) diagnosis (Kwong et al., 2005) CHFR NYC primary tumor biopsise MSP MSP 73% (R11) diagnosis (Kwong et al., 2005) CHFR NYC primary tumor biopsise MSP MSP 73% (R11) diagnosis (Kwong et al., 2005) CHR NYC primary tumor biopsise MSP MSP 73% (R11) diagnosis (Kwong et al., 2007) LTF NYC primary tumor biopsise MSP 89% (C123) diagnosis (Liu et al., 2006) CDH11 NYC primary tumor biopsise MYC cell lines MSP 100% diagnosis (Liu et al., 2008) RFS NYC primary tumor biopsise MYC cell lines MSP 100% diagnosis (Liu et al., 2010)	MGM1 MLH1	NPC primary tumor biopsies	MSP MSP	28% 40%	diagnosis	(Wong et al., 2003b) (Wong et al., 2003b)
MAT mining fluid $\frac{30\%}{20\%}$ RIZINPC parafilin and/or brushingMSP 56.60% RIZINPC primary tumor biopsicsMSP 55.60% CHIPRNPC primary tumor biopsicsMSP 55.60% GADD45GNPC primary tumor biopsicsMSP 73% (8/43)GAD45GNPC primary tumor biopsicsMSP 73% (8/43)GAD45GNPC primary tumor biopsicsMSP 73% (8/43)GAD45GNPC primary tumor biopsicsMSP 54.2% (874)GAD45GNPC primary tumor biopsicsMSP 54.2% (874)GAD45GNPC primary tumor biopsicsMSP 75% (8/43)MSP 10% (8/43)diagnosis(Kwong et al., 2005)CHRNPC primary tumor biopsicsMSP 77% NPC (educinic and sporadic types) 89% (6/72)(SagnosisCH113NPC primary tumor biopsicsMSP 100% (1/5)NPC (cell lines)MSP 100% (2/2)NPC vacografts 100% (1/3)MR field blood samplesMSP 100% (1/3)MR field blood samplesMSP 77% (2/36)MR field blood samplesMSP 75% (2/36)MR field blood samplesMSP 77% (2/36)MR field blood samples	p15	NPC primary tumor biopsies	MSP	50-80%	diagnosis	(Chang et al., 2003b; Wong et al., 2003b)
RZI Plantial THBS1MSP to primary tumor biopsicsMSP MSP to primary tumor biopsicsCharge rel. 20% diagnosisCharge rel. 2003b)CHFR NCC cell linesMSP to primary tumor biopsicsMSP to primary tumor biopsicsRFA to prim		M&T rinsing fluid		40%		
THBS1 NPC primary tumor biopsies MSP 50% diagnosis (Wong et al., 2003b) CHFR NPC primary tumor biopsies MSP 20% diagnosis (Chernor biopsies) GADD45G NPC primary tumor biopsies MSP 73% (Namor biopsies) (Namor biopsies) CHFR NPC primary tumor biopsies MSP 73% (Namor biopsies) (Namor biopsies) (Namor biopsies) CRBPs NPC primary tumor biopsies MSP 73% (Namor biopsies) (Namor biopsies) (Namor biopsies) DLC1 NPC primary tumor biopsies MSP 73% (G123) (diagnosis) (Ying et al., 2006) CDH1 NPC primary tumor biopsies MSP 82% (G472) (Gagnosis) (Ying et al., 2006) CDH1 NPC primary tumor biopsies MSP 73% (diagnosis) (Liu et al., 2007) MCC primary tumor biopsies MSP 73% (diagnosis) (Liu et al., 2008) MRF NPC primary tumor biopsies MSP 73% (diagnosis) (Liu et al., 2007) MCC primary tumor biopsies MSP 73% (diagnosis) (Liu et	RIZ1	NPC paraffin and/or brushing	MSP	20% 56.60%	diagnosis	(Chang et al., 2003a; Hutajulu et al., 2011)
CHFRNPC brimary lumor biopsicsMSP61.1% (2276)diagnosis(Cheung et al., 2005)GADD45GNPC primary lumor biopsicsMSP73% (8/11)diagnosis(Cheung et al., 2005)CRBPNPC primary lumor biopsicsMSP54.2% 87.8%diagnosis(Kwong et al., 2005)CRBPNPC primary lumor biopsicsMSP54.2% 87.8%diagnosis(Kwong et al., 2005)DLC1NPC chedmic and sporadic types)89% (64/72)(Gagnosis(Huightide al., 2011)NPC chedmic and sporadic types)98% (64/72)(Gagnosis(Sun et al., 2006)PCDH10NPC primary lumor biopsicsMSP82%diagnosis(Sun et al., 2006)PCDH10NPC primary lumor biopsicsMSP80% (64/72)(Gagnosis(Liu et al., 2006)PCDH10NPC primary lumor biopsicsMSP100%(diagnosis(Liu et al., 2008)RFNNPC cell lines100%(diagnosis(Liu et al., 2008)RFNNPC primary lumor biopsicsMSP7% (3/46)(diagnosis(Liu et al., 2008)LARS2NPC primary lumor biopsicsMSP64% (270)(diagnosis(Cong et al., 2010)DAB2NPC primary lumor biopsicsMSP64% (270)(diagnosis(Marg et al., 2011)DAB2NPC primary lumor biopsicsMSP65% (6770)(diagnosis(Marg et al., 2011)DAB2NPC primary lumor biopsicsMSP65% (6770)(diagnosis(Liu et al., 2011)DAB4NPC primary lumor biopsicsMSP65% (6770)	THBS1 TP73	NPC primary tumor biopsies	MSP MSP	50% 20%	diagnosis	(Wong et al., 2003b) (Wong et al., 2003b)
$ GADDAG MPC cell lines MSP 73% (UV_P) diagnosis (Kwong et al., 2005)CRBPs NPC primary tumor biopsics MSP 73% (S^{0}(3) diagnosis (Kwong et al., 2005a)DLC1 NPC primary tumor biopsics MSP 73% (S^{0}(3) diagnosis (Kwong et al., 2005b)DLC1 NPC primary tumor biopsics MSP 73% (S^{0}(3) diagnosis (Ving et al., 2005b)DLC1 NPC primary tumor biopsics MSP 73% (S^{0}(3) diagnosis (Ving et al., 2005b)DLC1 NPC primary tumor biopsics MSP 73% (S^{0}(3) diagnosis (Ving et al., 2005b)DLC1 NPC primary tumor biopsics MSP 73% (S^{0}(3) diagnosis (Ving et al., 2005b)DLC1 NPC primary tumor biopsics MSP 73% (S^{0}(3) diagnosis (Ving et al., 2005b)NPC cell lines NPC cell lines NPP 78% (S^{0}(3) diagnosis (Ving et al., 2007b)NPC cell lines NPP 78% (S^{0}(3) diagnosis (Uur et al., 2007b)MSP 78% (S^{0}(3) diagnosis (Uur et al., 2008b)MSP 78% (S^{0}(3) diagnosis (Uur et al., 2008b)H4-3-3 signa NC primary tumor biopsies MSP 86% (S^{0}(2) diagnosis (Uur et al., 2010b)MSP 72% (S^{0}(3) diagnosis (Uur et al., 2010b)NPC cell lines MSP 72% (S^{0}(4) diagnosis (Uur et al., 2010b)NPC cell lines MSP 86% (S^{0}(7) diagnosis (Uur et al., 2011b)NPC cell lines MSP 86% (S^{0}(7) diagnosis (Uur et al., 2011b)NPC cell lines MSP 85% (S^{0}(7) diagnosis (Uur et al., 2011b)NPC cell lines MSP 85% (S^{0}(5) diagnosis (Uur et al., 2011b)NPC cell lines MSP 85% (S^{0}(5) diagnosis (Uur et al., 2011b)NPC cell lines MSP 75% (S^{0}(5) diagnosis (Uur$	CHFR	NPC primary tumor biopsies	MSP	61.1% (22/36)	diagnosis	(Cheung et al., 2005)
TIG1 NPC primary tumor biopsies MSP 90.7% (39/43) diagnosis (Kwong et al., 2005b) DLC1 NPC primary tumor biopsies MSP 79% (31/39) diagnosis (Kwong et al., 2005b) DLC1 NPC primary tumor biopsies MSP 79% (61/75) (Hanglud et al., 2011) TFF NPC primary tumor biopsies MSP 82% (21/33) diagnosis (Ying et al., 2006) DCD1 NPC primary tumor biopsies MSP 82% (21/33) diagnosis (Sun et al., 2006) DCD1 NPC cell lines 20% (1/5) diagnosis (Lin et al., 2008) MPC primary tumor biopsies MSP 100% (22) diagnosis (Lin et al., 2008) H4-33 sigma NPC cell lines 100% diagnosis (Lin et al., 2009) LARS2 NPC primary tumor biopsies MSP 78% diagnosis (Dong et al., 2007) LARS2 NPC cell lines MSP 78% diagnosis (Dong et al., 2006) LARS2 NPC primary tumor biopsies MSP 64% (22) diagnosis (Doug et al., 2010) CADM1 NPC cell lines MSP 56% (67/20) diagnosis (GADD45G	NPC cell lines NPC primary tumor biopsies	MSP	100% 73% (8/11)	diagnosis	(Ying et al., 2005)
DLC1 NPC primary numor biopsize MSP 77% (31/39) diagnosis (Heuglul et al., 2006) NPC endemic and sporadic types) NPP 89% (64/72) (Gagnosis) (Yng et al., 2006) CH11 NPC primary tumor biopsizes MSP 82% diagnosis (Yng et al., 2006) CDH13 NPC primary tumor biopsizes MSP 82% diagnosis (Surg et al., 2006) DPC primary tumor biopsizes MSP 20% (1/2) diagnosis (Liu et al., 2007) DR7 NPC primary tumor biopsizes MSP 100% diagnosis (Liu et al., 2008) RF8 NPC primary tumor biopsizes MSP 100% diagnosis (Liu et al., 2009) LA823 NPC primary tumor biopsizes MSP 64% (2/2) diagnosis (Liu et al., 2009) LA823 NPC primary tumor biopsizes MSP 64% (2/2) diagnosis (Uong et al., 2010) LA823 NPC primary tumor biopsizes MSP 64% (2/2) diagnosis (Uong et al., 2011) LA823 NPC primary tumor biopsizes MSP 64% (2/2) diagnosis (Uong et al., 2011) LA824 NP	TIG1 CRBPs	NPC primary tumor biopsies	MSP MSP	90.7% (39/43) 54.2% 87.8%	diagnosis	(Kwong et al., 2005a) (Kwong et al., 2005b)
MC parathn and/or brushing MSP 7/% (Hutayub et al., 2011) ITF NCC (andenic and sporadic types) 63.6% (21.72) (diagnosis (Yret al., 2007) CDH13 NCC primary numer biopsies MSP 89.7% (52.25) (diagnosis (Yret al., 2007) NCC cell lines MSP 89.7% (52.25) (diagnosis (Yret al., 2007) RFA Matched blood samples MSP 100% (Liu et al., 2008) RFA NPC cell lines MSP 100% (Liu et al., 2008) 14.3-3 sigma NPC primary tumor biopsies MSP 100% (Liu et al., 2009) 14.3-3 sigma NPC primary tumor biopsies MSP 100% (Liagnosis (Lou et al., 2009) 14.3-3 sigma NPC primary tumor biopsies MSP 72% (33/46) (diagnosis (Tong et al., 2010) CABM NPC primary tumor biopsies MSP 94.86% (diagnosis (Dou et al., 2011) DHA prantin and/or brushing MSP 64.7% (23/46) (diagnosis (Dou et al., 2011) CABM NPC cell lines MSP 74.86% (diagnosis (Dou et al., 2011)	DLC1	NPC primary tumor biopsies	MSP	79% (31/39)	diagnosis	(Peng et al., 2006)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		NPC paraffin and/or brushing NPC (endemic and sporadic types)	MSP	89% (64/72)		(Hutajulu et al., 2011) (Seng et al., 2007)
CDH13 NPC primary numer biopies MSD 80.7% (3278) clagnosis Came et al., 2007) NPC cell lines 100% (22) BRD NPC primary numer biopies MSP 100% (Liu et al., 2008) RF8 NPC primary numer biopies MSP 100% diagnosis (Liu et al., 2008) 14-3-3 sigma NPC primary numer biopies MSP 100% diagnosis (Ziu et al., 2009) LARS2 NPC primary numer biopies MSP 84% prognosis (Yi et al., 2009) LARS2 NPC primary numer biopies MSP 86% (270) diagnosis (Lou et al., 2010) DAB2 NPC primary numer biopies MSP 86% (270) diagnosis (Du et al., 2010) CADM1 NPC ecil lines MSP 94.30% diagnosis (Du et al., 2011) DH4 NPC primary numer biopies MSP 95.85% diagnosis (Du et al., 2011) CHFR NPC primary numer biopies MSP 58% (35/41) diagnosis (Lutajulu et al., 2011) Myocardin NPC primary numer biopies MSP 100% (32/4) diagnosis (Lu et al., 2011)	LTF PCDH10	NPC primary tumor biopsies	MSP	63.6% (21/33)	diagnosis	(Yi et al., 2006) (Ying et al., 2006)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	CDH13	NPC primary tumor biopsies	MSP	89.7% (52/58)	diagnosis	(Sun et al., 2007)
BRD7NPC primary tumor biopsies Marched block samplesMSP100% 100%diagnosis(Liu et al., 2008)IRF8NPC primary tumor biopsies NPC cell linesMSP78% 100%diagnosis(Le et al., 2009)14-3-3 sigmaNPC primary tumor biopsies NPC cell linesMSP84% 84% 97000isprognosis(Yi et al., 2009)LARS2NPC primary tumor biopsies NPC cell linesMSP64% 64%(23/36)diagnosis(Tong et al., 2010)LARS2NPC primary tumor biopsies MSPMSP66.7% 66.7%(diagnosis)(Tong et al., 2010)CADM1NPC cell lines primary tumor biopsiesMSP69.80% 66.7%diagnosis(Hutajulu et al., 2011)CHFR NPC cell linesMSP58.50% 100%diagnosis(Hutajulu et al., 2011)CHFR NPC cell linesNSP73.8% 100%(diagnosis)(Hutajulu et al., 2011)Myocardin NPC cell linesMSP61.29% 100%(diagnosis)(Li et al., 2011)MVC cell linesMSP61.29% 100%(diagnosis)(Li et al., 2011)NPC cell linesMSP61.29% 100%(diagnosis)(He et al., 2012)NPC cell linesMSP74.3% 100%(diagnosis)(U et al., 2013) <tr<< td=""><td></td><td>NPC cell lines NPC xenografts</td><td></td><td>20% (1/5) 100% (2/2)</td><td></td><td></td></tr<<>		NPC cell lines NPC xenografts		20% (1/5) 100% (2/2)		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	BRD7	NPC primary tumor biopsies Matched blood samples	MSP	100% 100%	diagnosis	(Liu et al., 2008)
14-3-3 sigmaNC cert linesMSP100% 100%(Yi et al., 2009)LARS2 NC cell linesMSP64%100% 100%(diagnosis (diagnosis)(Zhou et al., 2009)LARS2 DAB2NC primary tumor biopsiesMSP72%63/36 100%(diagnosis)(Dong et al., 2010)CADM1 CDH4NPC cell linesMSP88.6% 62.761(diagnosis)(Wang et al., 2011)CADM1 CDH4NPC pertrain and/or brushing NPC cell linesMSP94.30% 64.7%(diagnosis)(Hutajulu et al., 2011)CHFR MyocardinNPC pertrain and/or brushing MyocardinMSP58.50% 64.8%(diagnosis)(Hutajulu et al., 2011)LTF MyocardinNPC primary tumor biopsies MSPMSP73.8%(48/65)(diagnosis)(Li et al., 2011)NOR1 NPC cell linesMSP61.9% 61.9%(13/21)(diagnosis)(Li et al., 2011)NOR1 NPC primary tumor biopsies NPC cell linesMSP61.20% 100% (15/3)(diagnosis)(Hutajulu et al., 2011)NOR1 NPC cell linesMSP61.20% 100% (5/3)(diagnosis)(Mo et al., 2012)NPC cell lines NPC cell linesMSP100% (5/3)(diagnosis)(Wo et al., 2013)NPC cell lines NPC cell linesMSP74.3% (26/35)(diagnosis)(Wo et al., 2013)NPC cell lines NPC cell linesMSP75.% (3/4)(diagnosis(You et al., 2013)NPC cell lines NPC cell linesMSP75.5% (3/4)(diagnosis)(You et al., 2013) <tr< td=""><td>IRF8</td><td>NPC primary tumor biopsies</td><td>MSP</td><td>78%</td><td>diagnosis</td><td>(Lee et al., 2008)</td></tr<>	IRF8	NPC primary tumor biopsies	MSP	78%	diagnosis	(Lee et al., 2008)
ARECNPCCell linesMSP64%(23/36)diagnosis(Zhou et al., 2009)DAB2NPC primary tumor biopsiesMSP72%(33/46)diagnosis(Tong et al., 2010)NPC cell linesNPC primary tumor biopsiesMSP88.6%(62/70)diagnosis(Hutajulu et al., 2011)CADM1NPC paraffin and/or brushingMSP94.30%diagnosis(Hutajulu et al., 2011)CDH4NPC per affin and/or brushingMSP58.50%diagnosis(Hutajulu et al., 2011)CHFRNPC cell lines100%(77)diagnosis(Liutajulu et al., 2011)CHFRNPC cell linesMSP58.50%diagnosis(Chen et al., 2011)MyocardinNPC cell linesMSP61.9% (13/21)diagnosis(Li et al., 2011)MVC cell linesMSP61.9% (13/21)diagnosis(Li et al., 2011)NOR1NPC cell linesMSP61.20%diagnosis(Hutajulu et al., 2011)NPC cell linesMSP61.20%diagnosis(Hutajulu et al., 2011)NPC cell linesMSP61.20%diagnosis(Worg et al., 2012)NPC cell linesMSP52.50%diagnosis(Worg et al., 2013)NPC cell linesMSP52.50%diagnosis(You et al., 2013)DLECICell-free circulating DNAMSP52.50%diagnosis(Tian et al., 2013)CEX10NPC primary tumor biopsiesMSP75.5% (37/49)diagnosis(Tian et al., 2013)CDLF10Primary t	14-3-3 sigma	NPC primary tumor biopsies	MSP	84%	prognosis	(Yi et al., 2009)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	LARS2	NPC cell lines NPC primary tumor biopsies	MSP	100% 64% (23/36)	diagnosis	(Zhou et al., 2009)
ITTP2NDC cell linesIND0007/(1/b)diagnosis(Wang et al., 2010)CADM1NPC cell linesMSP69.80%diagnosis(But et al., 2011)CDH4NPC cell lines100%(Bagnosis(But et al., 2011)NPC cell lines100%(Iagnosis(Chen et al., 2011)MyocardinNPC primary tumor biopsiesMSP75.85%(As65)MyocardinNPC cell lines100% (7/7)(Iagnosis(Li et al., 2011)NPC cell linesMSP75.85%(As65)(Iagnosis(Li et al., 2011)NPC cell linesMSP61.20%(Iagnosis(Li et al., 2011)NPC cell linesMSP61.20%(Iagnosis(Li et al., 2011)NPC cell linesMSP85.3% (35/41)(Iagnosis(Hutajulu et al., 2011)NPC cell linesMSP74.3% (26/35)(Iagnosis(Mo et al., 2012)CACNA2D3NPC primary tumor biopsiesMSP52.50%(Iagnosis(Wong et al., 2013)DLECICell linesMSP75.5% (12/16)(Iagnosis(Su et al., 2013)SOX11NPC primary tumor biopsiesMSP75.5% (12/16)(Iagnosis(Su et al., 2013)SOX11NPC primary tumor biopsiesMSP75.5% (29/43)(Iagnosis(Iagnosis(IagnosisSOX11NPC primary tumor biopsiesMSP75.5% (29/43)(Iagnosis(Iagnosis(IagnosisSOX11NPC primary tumor biopsiesMSP75.5% (29/43)(Iagnosis(Iagnosis(Iagnosis(Iagnosis	DAB2 TEPL 2	NPC primary tumor biopsies	MSP MSP	72% (33/46)	diagnosis	(Tong et al., 2010) (Wang et al., 2010)
CADM1NPC primary tumor biopsies NPC cell linesMSP09.80% 100%(Hutajulu et al., 2011) (Du et al., 2011)CHFRNPC primary tumor biopsies NPC cell linesMSP94.30% 100%(Jagnosis(Du et al., 2011) (Zhang et al., 2011)LTFNPC cell linesMSP73.8%(48/65)(Jagnosis(Chen et al., 2011)MyocardinNPC primary tumor biopsies NPC cell linesMSP73.8%(48/65)(Jagnosis(Chen et al., 2011)NOR1NPC primary tumor biopsies NPC cell linesMSP61.20%(Jagnosis(Li et al., 2011)NOR1NPC primary tumor biopsies NPC cell linesMSP61.20%(Jagnosis(Hutajulu et al., 2011)RRADNPC primary tumor biopsies NPC cell linesMSP61.20%(Jagnosis(Hutajulu et al., 2011)RRADNPC primary tumor biopsies NPC cell linesMSP74.3%(26/55)(Jagnosis(Wo et al., 2013)CACNA2D3NPC primary tumor biopsies NPC cell linesMSP52.50%(Jagnosis(You et al., 2013)CDK10NPC primary tumor biopsies NPC cell linesMSP75.5%(37/49)(Jagnosis(Tian et al., 2013)CDK10NPC primary tumor biopsies NPC primary tumor biopsiesMSP67.4%(29/43)(Jagnosis(Tian et al., 2013)CH110NPC primary tumor biopsies NPC cell linesMSP67.4%(29/44)(Jagnosis(Jagnosis(Li et al., 2014)SOX11NPC primary tumor biopsies NPC primary tumor biopsiesMSP67.4% <td>CADM1</td> <td>NPC cell lines</td> <td>MCD</td> <td>66.7% (4/6)</td> <td>diagnosis</td> <td></td>	CADM1	NPC cell lines	MCD	66.7% (4/6)	diagnosis	
NPC cell lines100%LTFNPC paraffin and/or brushingMSPMyocardinNPC cell linesMSPNOR1NPC primary tumor biopsiesMSPNOR1NPC primary tumor biopsiesMSPNOR1NPC primary tumor biopsiesMSPMSP61.9%(13/21)diagnosis(Li et al., 2011)WIF1NPC paraffin and/or brushingMSPNPC cell linesMSPNPC cell linesMSP100% (5/5)diagnosisCACNA2D3NPC primary tumor biopsiesMSP100% (5/5)MSP100% (5/3)CDK10NPC cell linesMSP75.5% (37/49)diagnosis(Tian et al., 2013)CDK10NPC primary tumor biopsiesMSP74.3% (26/35)diagnosis(Shu et al., 2013)CDK10NPC primary tumor biopsiesMSP75.5% (37/49)diagnosis(Shu et al., 2013)TTC40NPC primary tumor biopsiesMSP61.4% (27/49)diagnosis(Li et al., 2014)LOXNPC primary tumor biopsiesMSP61.4% (27/49)diagnosis(Li et al., 2014)LOXNPC primary tumor biopsies </td <td>CDH4</td> <td>NPC parallin and/or brushing NPC primary tumor biopsies</td> <td>MSP</td> <td>94.30%</td> <td>diagnosis</td> <td>(Hutajulu et al., 2011) (Du et al., 2011)</td>	CDH4	NPC parallin and/or brushing NPC primary tumor biopsies	MSP	94.30%	diagnosis	(Hutajulu et al., 2011) (Du et al., 2011)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	CHFR	NPC cell lines	MSP	100% 58.50%	diagnosis	(Hutainlu et al. 2011)
MyCerardinMyC PPC cell linesMSP7.5.8% (4305) 4 of 5 (80%)diagnosis(Chen et al., 2011)NOR1NPC cell linesMSP61.9% (13/21) 100% (4/4)diagnosis(Li et al., 2011)WIF1NPC paraffin and/or brushing NPC cell linesMSP61.20% 100% (5/5)diagnosis(Hutajulu et al., 2011)PCDH8NPC primary tumor biopsies NPC cell linesMSP61.20% 100% (5/5)diagnosis(He et al., 2012)RADNPC primary tumor biopsies NPC cell linesMSP74.3% (26/35)diagnosis(Wo et al., 2013)DLEC1Cell-free circulating DNA masal swabMSP52.50% 100% (3/3)diagnosis(You et al., 2013)DLEC1Cell-free circulating DNA masal swabMSP75.5% (12/16)diagnosis(Shu et al., 2013)TC40NPC primary tumor biopsies mirary tumor biopsies NPC cell linesMSP74.4% (29/43)diagnosis(Shu et al., 2013)TC40NPC primary tumor biopsies NPC primary tumor biopsies NPC cell linesMSP71.12% (32/45)diagnosis(Sung et al., 2014)IC44NPC primary tumor biopsies NPC cell linesMSP55.9% (37/45)diagnosis(Li et al., 2014)IC44NPC primary tumor biopsies NPC cell linesMSP52.6%diagnosis(Li et al., 2014)IC44NPC primary tumor biopsies NPC cell linesMSP64.90%diagnosis(Li et al., 2014)IC44NPC primary tumor biopsies NPC cell linesMSP56.9% (37/65)diagnosis(Li e	LTF	NPC cell lines	MCD	100% (7/7)	diagnosis	(Zhang et al., 2011) Chang et al., 2011)
NOR1NPC primary tumor biopsies NPC cell linesMSP61.9% (13/21) 100% (4/4)diagnosis(Li et al., 2011b)WIF1NPC primary tumor biopsies NPC cell linesMSP61.20% 61.20%diagnosis(Hutajulu et al., 2011)PCDH8NPC primary tumor biopsies NPC cell linesMSP85.3% (35/41) 100% (5/5)diagnosis(He et al., 2012)RRADNPC primary tumor biopsies NPC cell linesMSP74.3% (26/35) 100% (5/5)diagnosis(Mo et al., 2013)CACNA2D3NPC primary tumor biopsies nasal swabMSP52.50% 15.5% (37/49)diagnosis(You et al., 2013)CDK10NPC primary tumor biopsies nasal swabMSP75.5% (37/49) 15.5% (12/16)diagnosis(Shu et al., 2013)SOX11NPC primary tumor biopsies nasal swabMSP75.5% (12/16)diagnosis(Tian et al., 2013)TTC40NPC primary tumor biopsies NPC primary tumor biopsies NPC primary tumor biopsiesMSP71.12% (32/45)diagnosis(Li et al., 2014)LOXNPC primary tumor biopsies NPC cell linesMSP75.5% (37/49)diagnosis(Li et al., 2014)NPC primary tumor biopsies NPC primary tumor biopsiesMSP75.5% (37/49)diagnosis(Li et al., 2014)LOXNPC primary tumor biopsies NPC cell linesMSP71.12% (32/45)diagnosis(Li et al., 2014)NPC primary tumor biopsies NPC cell linesMSP72.5% (42/49)diagnosis(Li et al., 2014)NPC primary tumor biopsies NPC cell linesMSP56	Myocardin	NPC cell lines	MSP	4 of 5 (80%)	diagnosis	(Chen et al., 2011)
WIF1NPC paraffin and/or brushing NPC cell linesMSP61.20% MSPdiagnosis(Hutajulu et al., 2011)PCDH8NPC primary tumor biopsiesMSP85.3% (35/41) 100% (5/5)diagnosis(He et al., 2012)RRADNPC primary tumor biopsiesMSP74.3% (26/35)diagnosis(Mo et al., 2012)CACNA2D3NPC primary tumor biopsiesMSP100% (5/5)diagnosis(Wong et al., 2013)CDK10NPC primary tumor biopsiesMSP52.50%diagnosis(You et al., 2013)DLEC1Cell-free circulating DNAMSP25.00%diagnosis(Shu et al., 2013)SOX11NPC primary tumor biopsiesMSP75.5% (37/49)diagnosis(Tian et al., 2013)SOX11NPC primary tumor biopsiesMSP64.90%diagnosis(Tian et al., 2013)TC40NPC primary tumor biopsiesMSP75.7% (42/49)diagnosis(Ayadi et al., 2014)LOXNPC primary tumor biopsiesMSP85.7% (42/49)diagnosis(Sung et al., 2014)Nose swab18.75% (37/45)diagnosis(Li et al., 2014a)NPC cell linesNSP82.2% (37/45)diagnosis(Li et al., 2014)NPC cell linesMSP56.5% (37/65)diagnosis(Yaug et al., 2014)NPC cell linesMSP57.5% (23/40)diagnosis(Xiao et al., 2014)NPC primary tumor biopsiesMSP57.5% (23/40)diagnosis(Yaug et al., 2014)NPC cell linesNPC primary tumor biopsiesMSP57.5% (23/40)	NOR1	NPC primary tumor biopsies NPC cell lines	MSP	61.9% (13/21) 100% (4/4)	diagnosis	(Li et al., 2011b)
PCDB'sNPC primary tumor biopsiesMSP35.3% (35.4%)(Hagnosis)(He et al., 2012)NPC cell lines100% (5/5)diagnosis(Mo et al., 2012)CACNA2D3NPC primary tumor biopsiesMSP100% (5/5)diagnosis(Wong et al., 2013)NPC cell lines100% (3/3)100% (3/3)(Shu et al., 2013)CDK10NPC primary tumor biopsiesMSP52.50%diagnosis(Tian et al., 2013)DLEC1Cell-free circulating DNAMSP25.00%diagnosis(Shu et al., 2013)SOX11NPC primary tumor biopsiesMSP75.5% (37/49)diagnosis(Shu et al., 2013)SOX11NPC primary tumor biopsiesMSP64.90%diagnosis(Tian et al., 2013)TC40NPC primary tumor biopsiesMSP77% (32/45)diagnosis(Sung et al., 2014)Nose swabMSP85.7% (37/45)diagnosis(Sung et al., 2014)Nose swabMSP85.7% (37/45)diagnosis(Li et al., 2014)NPC cell linesMSP80% (4/5)4(30)(Sing et al., 2014)NPC cell linesMSP56.9% (37/65)diagnosis(Li et al., 2014)NPC cell linesMSP57.5% (29/40)diagnosis(Yang et al., 2014)NPC cell linesMSP72.5% (29/40)diagnosis(Yang et al., 2014)NPC cell linesMSP57.5% (23/40)diagnosis(Yang et al., 2014)NPC cell linesMSP57.5% (23/40)diagnosis(Yang et al., 2014)NPC cell linesMS	WIF1	NPC paraffin and/or brushing	MSP	61.20%	diagnosis	(Hutajulu et al., 2011)
RRADNPC primary tumor biopsiesMSP/4.3% (26/35)diagnosis(Mo et al., 2012)CACNA2D3NPC primary tumor biopsiesMSP100% (5/5)diagnosis(Wong et al., 2013)CDK10NPC primary tumor biopsiesMSP52.50%diagnosis(Tian et al., 2013)DLEC1Cell-free circulating DNAMSP75.5% (37/49)diagnosis(Shu et al., 2013)FEZF2NPC primary tumor biopsiesMSP75.5% (37/49)diagnosis(Shu et al., 2013)OX11NPC primary tumor biopsiesMSP64.90%diagnosis(Tian et al., 2013)UCHL1Cell-free circulating DNAMSP64.90%diagnosis(Tian et al., 2014)NCF primary tumor biopsiesMSP71.12% (32/45)diagnosis(Sung et al., 2014)Nose swabMSP85.7% (42/49)diagnosis(Sung et al., 2014)Nose swabBisulfite sequencing 53-97%diagnosis(Li et al., 2014)NPC primary tumor biopsiesMSP56.9% (37/65)diagnosis(Li et al., 2014)NPC cell linesMSP56.9% (37/65)diagnosis(Xiao et al., 2014)WWOXNPC primary tumor biopsiesMSP72.5% (29/40)diagnosis(Yaug et al., 2014)NPC cell linesMSP72.5% (29/40)diagnosis(Yaug et al., 2014)NPC cell linesMSP72.5% (29/40)diagnosis(Yaug et al., 2014)NPC cell linesMSP72.5% (29/40)diagnosis(Yaug et al., 2015)PCDH20NPC primary tumor biopsies<		NPC cell lines	MGD	100% (5/5)		(110 ct al., 2012)
NPC cell lines100% (3/3)c(10% (3/3)CDK10NPC primary tumor biopsiesMSP52.50%diagnosis(You et al., 2013)DLEC1Cell-free circulating DNAMSP25.00%diagnosis(Tian et al., 2013)FEZF2NPC primary tumor biopsiesMSP75.5% (37/49)diagnosis(Shu et al., 2013)SOX11NPC primary tumor biopsiesMSP67.4% (29/43)diagnosis, prognosis(Zhang et al., 2013)UCHL1Cell-free circulating DNAMSP64.90%diagnosis(Tian et al., 2013)UCHL1Cell-free circulating DNAMSP64.90%diagnosis(Ayadi et al., 2014)Nose swabMSP75.5% (3/16)diagnosis(Sung et al., 2014)Nose swabNose swab18.75% (3/16)diagnosis(Li et al., 2014)miR-148aNPC primary tumor biopsiesBisulfite sequencing53-97%diagnosis(Li et al., 2014)NPC cell linesMSP56.9%(3/765)diagnosis(Yang et al., 2014)WWOXNPC primary tumor biopsiesMSP50.9%(3/765)diagnosis(Yang et al., 2014)WWOXNPC primary tumor biopsiesMSP72.5% (29/40)diagnosis(Yang et al., 2014)NPC cell lines100%(6/6)57.5% (23/40)diagnosis(Yang et al., 2015)PCDH20NPC primary tumor biopsiesMSP72.5% (29/40)diagnosis(Chen et al., 2015)NPC cell linesMSP56%diagnosis(Chen et al., 2015)NPC cell linesMSP56% <td>RRAD CACNA2D3</td> <td>NPC primary tumor biopsies</td> <td>MSP MSP</td> <td>100% (5/5)</td> <td>diagnosis</td> <td>(Mo et al., 2012) (Wong et al., 2013)</td>	RRAD CACNA2D3	NPC primary tumor biopsies	MSP MSP	100% (5/5)	diagnosis	(Mo et al., 2012) (Wong et al., 2013)
CDER10CP primary fumor biopsiesMSP22.30%diagnosis(Tou et al., 2013)FEZF2NPC primary tumor biopsiesMSP75.5% (37/49)diagnosis(Tian et al., 2013)SOX11NPC primary tumor biopsiesMSP67.4% (29/43)diagnosis, prognosis(Zhang et al., 2013)UCHL1Cell-free circulating DNAMSP64.90%diagnosis(Tian et al., 2013)UCHL1Cell-free circulating DNAMSP64.90%diagnosis(Tian et al., 2013)UCHL1Cell-free circulating DNAMSP64.90%diagnosis(Ayadi et al., 2014)LOXNPC primary tumor biopsiesMSP71.12% (32/45)diagnosis(Sung et al., 2014)Nose swabNose swab18.75% (3/16)diagnosis(Li et al., 2014)miR-148aNPC primary tumor biopsiesBisulfite sequencing 53-97%diagnosis(Li et al., 2014)NPC cell linesMSP50.9% (37/65)diagnosis(Li et al., 2014)WWOXNPC primary tumor biopsiesMSP50.9% (37/65)diagnosis(Xiao et al., 2014)VPC cell linesMSP52.9% (29/40)diagnosis(Xiao et al., 2014)NPC cell lines100% (6/6)57.5% (29/40)diagnosis(You et al., 2015)PCDH20NPC primary tumor biopsiesMSP78.4% (40/51)diagnosis(Chen et al., 2015)NPC cell linesMSP56%diagnosis(Nawaz et al., 2015a)	CDV 10	NPC cell lines	MSD	100% (3/3)	diagnosis	(Vou et al. 2012)
FEZF2NPC primary tumor biopsies nasal swabMSP7/5.%(3/49) 75% (12/16)diagnosis(Shu et al., 2013)SOX11NPC primary tumor biopsiesMSP67.4% (29/43)diagnosis, prognosis (Zhang et al., 2013)UCHL1Cell-free circulating DNAMSP64.90%diagnosis(Tian et al., 2013)TTC40NPC primary tumor biopsiesMSP71.12%(32/45)diagnosis(Ayadi et al., 2014)LOXNPC primary tumor biopsiesMSP85.7% (42/49)diagnosis(Sung et al., 2014)Nose swabNSP85.7% (42/49)diagnosis(Li et al., 2014)miR-148aNPC primary tumor biopsiesMSP82.2%(37/45)diagnosis(Li et al., 2014a)PTENNPC cell linesMSP56.9%(37/65)diagnosis(Yang et al., 2014)WWOXNPC primary tumor biopsiesMSP56.9%(37/65)diagnosis(Yaug et al., 2014)CYB5R2NPC cell lines100%(6/6)diagnosis(Yaug et al., 2014)PCCH20NPC primary tumor biopsiesMSP72.5% (29/40)diagnosis(You et al., 2015)FrenceNPC primary tumor biopsiesMSP72.5% (29/40)diagnosis(Chen et al., 2015)FrenceNPC primary tumor biopsiesMSP56%diagnosis(Nawaz et al., 2015a)	DLEC1	Cell-free circulating DNA	MSP	25.00%	diagnosis	(Tian et al., 2013)
SOX11NPC primary tumor biopsiesMSP 67.4% ($29/43$)diagnosis,prognosis (Zhang et al., 2013)UCHL1Cell-free circulating DNAMSP 64.90% diagnosis(Tian et al., 2013)TTC40NPC primary tumor biopsiesMSP $71.12\%(32/45)$ diagnosis(Ayadi et al., 2014)LOXNPC primary tumor biopsiesMSP $71.12\%(32/45)$ diagnosis(Sung et al., 2014)Nose swabMSP 85.7% ($42/49$)diagnosis(Li et al., 2014)miR-148aNPC primary tumor biopsiesMSP $82.2\%(37/45)$ diagnosis(Li et al., 2014)PTENNPC cell linesBisulfite sequencing 53.97% diagnosis(Li et al., 2014)WWOXNPC primary tumor biopsiesMSP $56.9\%(37/65)$ diagnosis(Yang et al., 2014)WWOXNPC primary tumor biopsiesMSP $56.9\%(37/65)$ diagnosis(Yang et al., 2014)CYB5R2NPC cell lines100\%(6/6)MSP 72.5% ($29/40$)diagnosis(You et al., 2015)PCDH20NPC primary tumor biopsiesMSP 72.5% ($29/40$)diagnosis(Chen et al., 2015)NPC cell linesMSP $88\%(4/5)$ MSP 56% diagnosis(Chen et al., 2015)ITGA9NPC primary tumor biopsiesMSP 56% diagnosis(Nawaz et al., 2015a)	FEZF2	NPC primary tumor biopsies	MSP	75.5%(37/49) 75% (12/16)	diagnosis	(Shu et al., 2013)
OctifiedCell-free chreat tumor biopsies Nose swabMSP71.12%(32/45)diagnosis (Ayadi et al., 2014)LOX Nose swabNPC primary tumor biopsies NPC primary tumor biopsies NPC cell linesMSP71.12%(32/45)diagnosis (Sung et al., 2014)WWOX CYB5R2 NPC cell linesNPC primary tumor biopsies NPC cell linesMSP85.7% (42/49)diagnosis (Li et al., 2014)WWOX CYB5R2 NPC cell linesNSP56.9%(37/45)diagnosis (Li et al., 2014)(Li et al., 2014)WWOX CYB5R2 NPC cell linesMSP56.9%(37/65)diagnosis (Vang et al., 2014)(Xiao et al., 2014)WPC primary tumor biopsies NPC cell linesMSP72.5% (29/40)diagnosis (Xiao et al., 2014)FCRG4 PCDH20NPC primary tumor biopsies NPC cell linesMSP72.5% (29/40)diagnosis (Vang et al., 2015)PCDH20 NPC primary tumor biopsies NPC cell linesMSP78.4% (40/51)diagnosis (Chen et al., 2015)FTGA9NPC primary tumor biopsies NPC primary tumor biopsiesMSP56%diagnosis(Chen et al., 2015a)	SOX11	NPC primary tumor biopsies	MSP MSP	67.4% (29/43)	diagnosis,prognosis	(Zhang et al., 2013) (Tion et al., 2013)
LOXNPC primary tumor biopsies Nose swabMSP85.7% (42/49) (18.75% (3/16)diagnosis(Sung et al., 2014)miR-148aNPC primary tumor biopsies NPC primary tumor biopsies NPC cell linesBisulfite sequencing53-97% MSPdiagnosis(Li et al., 2014a) (Li et al., 2014b)WWOXNPC primary tumor biopsies NPC cell linesMSP82.2%(37/45) 80% (4/5)diagnosis(Li et al., 2014b)WWOXNPC primary tumor biopsies NPC cell linesMSP56.9%(37/65) 80% (4/5)diagnosis(Yang et al., 2014)ECRG4NPC primary tumor biopsies Peripheral blood samples from the NPC patientsMSP72.5% (29/40) 57.5% (23/40)diagnosis(You et al., 2015)PCDH20NPC primary tumor biopsies NPC cell linesMSP78.4% (40/51) 80% (4/5)diagnosis(Chen et al., 2015)ITGA9NPC primary tumor biopsiesMSP56% 56%diagnosis(Nawaz et al., 2015a)	TTC40	NPC primary tumor biopsies	MSP	71.12%(32/45)	diagnosis	(Ayadi et al., 2013)
miR-148aNPC primary tumor biopsies NPC primary tumor biopsiesBisulfite sequencing 53-97% MSPdiagnosis (Li et al., 2014a) (Li et al., 2014b)PTENNPC primary tumor biopsies NPC cell linesBisulfite sequencing 53-97% MSPdiagnosis 80% (4/5)(Li et al., 2014a) (Li et al., 2014b)WWOXNPC primary tumor biopsies NPC cell linesMSP82.2%(37/45) 80% (4/5)diagnosis (Yang et al., 2014)ECRG4NPC primary tumor biopsies Peripheral blood samples from the NPC patientsMSP72.5% (29/40) 57.5% (23/40)diagnosis (You et al., 2015)PCDH20NPC primary tumor biopsies NPC cell linesMSP78.4% (40/51) 80% (4/5)diagnosis (Chen et al., 2015)ITGA9NPC primary tumor biopsiesMSP56% 56%diagnosis(Nawaz et al., 2015a)	LOX	NPC primary tumor biopsies Nose swab	MSP	85.7% (42/49) 18.75% (3/16)	diagnosis	(Sung et al., 2014)
ITENInfect primary funito biopsiesMSP36.2.3.4(37/45)diagnosis(Effect al., 2014)NPC cell lines80% (4/5)80% (4/5)diagnosis(Yang et al., 2014)CYB5R2NPC primary tumor biopsiesMSP84%(42/50)diagnosis(Xiao et al., 2014)NPC cell lines100%(6/6)100%(6/6)100%(6/6)100%(6/6)ECRG4NPC primary tumor biopsiesMSP72.5% (29/40)diagnosis(You et al., 2015)peripheral blood samples57.5 % (23/40)100%(6/5)100%(6/5)100%(6/5)PCDH20NPC patients80% (4/5)100%(6/5)100%(6/5)PCDH20NPC primary tumor biopsiesMSP78.4% (40/51)diagnosis(Chen et al., 2015)NPC cell lines80% (4/5)100%(6/5)100%(6/5)100%(6/5)ITGA9NPC primary tumor biopsiesMSP56%diagnosis(Nawaz et al., 2015a)	miR-148a	NPC primary tumor biopsies	Bisulfite	e sequencing 53-97%	diagnosis	(Li et al., 2014a)
WWOX NPC primary tumor biopsies MSP 56.9%(3/765) diagnosis (Yang et al., 2014) CYB5R2 NPC primary tumor biopsies MSP 84%(42/50) diagnosis (Xiao et al., 2014) ECRG4 NPC primary tumor biopsies MSP 72.5% (29/40) diagnosis (You et al., 2015) Feripheral blood samples 57.5% (23/40) from the NPC patients 57.5% (23/40) diagnosis (Chen et al., 2015) PCDH20 NPC primary tumor biopsies MSP 78.4% (40/51) diagnosis (Chen et al., 2015) ITGA9 NPC primary tumor biopsies MSP 56% diagnosis (Nawaz et al., 2015a)		NPC cell lines	MGD	80% (4/5)		
NPC cell lines100%(6/6)ECRG4NPC primary tumor biopsiesMSPPeripheral blood samples from the NPC patientsMSPPCDH20NPC primary tumor biopsiesMSP78.4% (40/51) NPC cell linesdiagnosisITGA9NPC primary tumor biopsiesMSP56%diagnosis(Nawaz et al., 2015a)	WWOX CYB5R2	NPC primary tumor biopsies NPC primary tumor biopsies	MSP MSP	56.9%(37/65) 84%(42/50)	diagnosis diagnosis	(rang et al., 2014) (Xiao et al., 2014)
Pertipheral blood samples MSP 72.5 % (23/40) Gragnosis (Fourteral, 2015) from the NPC patients 57.5 % (23/40) diagnosis (Chen et al., 2015) PCDH20 NPC primary tumor biopsies MSP 78.4% (40/51) diagnosis (Chen et al., 2015) ITGA9 NPC primary tumor biopsies MSP 56% diagnosis (Nawaz et al., 2015a)	ECRG4	NPC cell lines	MSP	100%(6/6) 72 5% (29/40)	diagnosis	(You et al. 2015)
PCDH20 NPC primary tumor biopsies MSP 78.4% (40/51) diagnosis (Chen et al., 2015) NPC cell lines 80% (4/5) ITGA9 NPC primary tumor biopsies MSP 56% diagnosis (Nawaz et al., 2015a)	LUNOT	Peripheral blood samples	141.91	57.5 % (23/40)	ulagilosis	(100 et al., 2015)
NPC cell lines80% (4/5)ITGA9NPC primary tumor biopsiesMSP56%diagnosis(Nawaz et al., 2015a)	PCDH20	NPC primary tumor biopsies	MSP	78.4% (40/51)	diagnosis	(Chen et al., 2015)
	ITGA9	NPC cell lines NPC primary tumor biopsies	MSP	80% (4/5) 56%	diagnosis	(Nawaz et al., 2015a)

Table 1. Summary of genes shown to be hypermethylated in nasopharyngeal carcinoma

MSP : methylation-specific polymerase chain reaction; M&T: mouth and throat; NP: nasopharyngeal

Wei Jiang et al

and primary tumors. Several subsequent studies using methylation-specific polymerase chain reaction (MSP) approaches to investigate the promoter methylation profile of p16 found methylation frequencies to be 23-66% in primary undifferentiated NPC(Ayadi et al., 2008; Challouf et al., 2012; Tian et al., 2013), 46.4% in nasopharyngeal (NP) brushings(Tong et al., 2002), and 42% in plasma DNA(Wong et al., 2004). There was a perfect concordance in methylation among corresponding samples. The results demonstrated that the methylation level in p16 was a potential diagnostic tool for the differential diagnosis between benign NP tissue and malignant NP tumors.

Another example of the potential use of hypermethylated DNA as a biomarker was the involvement of the methylated gene RASSF1A in the early detection of NPC. Lo et al. (Lo et al., 2001) used MSP analyses to investigate hypermethylation of promoter regions of RASSF1A in nasopharyngeal primary tumors, xenografts, and cell lines for the first time. Other reports also presented the methylation frequency of RASSF1A promoters to be as high as 39.3% in nasopharyngeal brushings, 46%-67% in primary undifferentiated NPC, 33% in nasopharyngeal swabs, 37% in mouth and throat (M&T) rinsing fluid, respectively (Chang et al., 2003b; Wong et al., 2003b). From these efforts, it is clear that this molecular event is an early and important marker of NPC.

In the past decade, a multitude of studies demonstrated that other classical TSGs undergo hypermethylation in various biologic samples of NPC, including RRAD, DAP-kinase, CDH13, E-cad, TIG1, CHFR, DAB2, Myocardin, TFPI-2 and CDH4 and so on (Chang et al., 2003b; Tsao et al., 2003; Cheung et al., 2005; Kwong et al., 2005a; Sun et al., 2007; Tong et al., 2010; Wang et al., 2010; Chen et al., 2011; Du et al., 2011; Mo et al., 2012), thereby rendering thier potential as alternative surrogate markers for the early diagnosis. We have summarized some examples of putative biomarkers in Table 1.

However, single epigenetic biomarkers are not sufficiently sensitive to detect early NPC accurately in tissue or body fluids, specific gene-methylation signatures have been suggested to improve sensitivity(Nawaz et al., 2015b). Hutajulu et al. applied quantitative profiling of DNA methylation in 10 TSGs in nasopharyngeal brushings and corresponding NPC paraffin-embedded tissue. The study found that combined analyses of five methylation markers (RASSF1A, p16, WIF1, CHFR and RIZ1) provided good discrimination between NPC and non-NPC with detection rate of 98% (Hutajulu et al., 2011). Myriam et al. used quantitative MSP to investigate promoter hypermethylation of 18 TSGs in NPC cell lines and NPC tumors biopsies. Authors suggested that combinatorial analyses of methylation of three genes (PGP9.5, KIF1A and DLEC) would detected NPC early with 84% sensitivity and 92% specificity (Loyo et al., 2011). In other methylation signature reports, the methyaltion level of four-gene marker (CDKN2A, DLEC1, DAPK1 and UCHL1) could early predict NPC with the highest sensitivity and specificity (Tian et al., 2013). A panel of four methylated genes (RASSF1A, WIF1, DAPK1 and RAR β 2) in combination with an EBV DNA marker significantly increased the prevalence of detection at an

early stage and local recurrence in NPC (Yang et al., 2015).

With recent developments in methods of highthroughput screening, several studies have evaluated genome-wide methylation profiling in NPC. Tao and colleagues using a whole-genome methylation platform newly identified hypermethylated genes SFRP1, 2 and 5, DACT1, DACT2 and DKK3 in NPC cell lines and primary tumors and suggested their potential value as biomarkers for NPC detection (Li et al., 2015a). Another genome-wide study in NPC demonstrated that the top 500 hypermethylated regions were frequently located at 6p21.3 in NPC. This region contains several important genes which could be used as biomarkers for NPC detection (Dai et al., 2015). Recently, our group also took a global methylation approach (the Illumina HumanMethylation450 BeadChip) to reveal both hyperand hypomethylation alterations are common events in NPC tumor tissues. As a result, 2173 CpG sites with methylation level change ≥ 0.2 (1880 hypermethylated, 293 hypomethylated) were identified (P < 0.05), as well as use of potential markers for early diagnosis in NPC (Jiang et al., 2015).

The studies mentioned above provide strong evidence that tumor promoter-specific hypermethylation is closely related with the development of NPC, and suggest DNA methylation biomarker that combines high sensitivity and specificity could be used for the early detection of NPC.

Marks for NPC Prognosis

DNA methylation profiles was shown with abilities to better defined the prognoses of numerous cancers(Ramos et al., 2010; You et al., 2010; Koga et al., 2011). Emerging research supports the notion that detection of aberrantly methylated genes in NPC can serve as biomarkers for the prognosis. In comparison, methylation of 14-3-3 sigma correlates with metastasis to lymph node and distant metastasis (Yi et al., 2009). WIF-1 methylation has been found to be associated with the tumor, node, and metastasis (TNM) classification (p=0.003) and age (p=0.014) (Fendri et al., 2010). In primary NPC tumors, clinical studies have revealed that aberrant promoter methylation of the three genes (RASSF1A, RAR^β2 and DAPK) are significantly associated with the lymph-node involvement (p<0.0001). In addition, hypermethylation of RASSF1A was found to be correlated with age at the diagnosis (p=0.047) and T stage (p= 0.037), whereas the RAR β 2 hypermethylation was associated with histological type (p = 0.011) (Fendri et al., 2009).

Latterly, our group examined the methylation level of paraffin-embedded specimens with NPC and provide reasonable assurance that the 6-hypermethylated gene panel (WIF1,UCHL1, RASSF1A, CCNA1, TP73 and SFRP1) was an independent prognostic factor in large sample size. The study revealed that NPC with high methylation level is associated with poorer survival and may increase the therapeutic options for patients diagnosed with NPC (Jiang et al., 2015)...

Clearly, the identification of new effective prognosis biomarkers for NPC will likely contribute to predict clinical outcomes and improved patient-tailored treatment. However, panels of candidate methylated-genes remain DNA Methylation Biomarkers for Nasopharyngeal Carcinoma: Diagnostic and Prognostic Tools

to be validated in the prospective study.

Targeting DNA methylation for epigenetic therapy in NPC

Epigenetic changes are reversible, making DNA methylation a potential target for anticancer therapies. During the past decade, a growing number of drugs targeting DNA methylation have been developed, for example, azacytidine (5-azacytidine, 5-Aza-CR), and decitabine (5-aza-2'-deoxycytidine, 5-Aza-CdR). These agents have been used as single agents or combined with other anticancer therapies and validated in multiple clinical trials to reduce global DNA methylation in vivo. In particular, trials on hematologic malignancies have shown higher response rates. Among preclinical studies for NPC, decitabine decreased survival of NPC cell lines (Li et al., 2011b; Zhang et al., 2013; Luo et al., 2015) and azacytidine enhanced the radiosensitivity of NPC cells by promoting cell apoptosis (Jiang et al., 2014). Moreover, decitabine treatment reactivated the methylated gene ECRG4 and enhanced chemosensitivity to cisplatin in NPC cells (You et al., 2015). However, until recently, no clinical trials have been the process to shown an association between the level of induced demethylation and clinical response in patients with NPC.

Conclusion

NPC continues to be a major public-health problem in the China and and south-eastern Asia. However, a lack of effective biomarkers for early detection and monitoring of NPC progression contributes to its adverse outcomes. After more than a decade of studies, DNA methyaltion, with characteristics of high stability and easy evaluation, has been shown to be a high-potential tool with great sensitivity and specificity in the diagnosis and prognosis of NPC, which will extend our ability to improve NPC management. Further high-powered studies with perspective clinical data are required to establish the role of DNA methylation for the diagnosis and prognosis of NPC.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 81560443), the Natural Science Foundation of Guangxi Zhuang Autonomous Region (No.2013GXNSFBA019155), the Guangxi Medical Scientific Experiment Center Open Fund (GK2014-TKF04), and the Scientific Research and Technology Development Program of Guilin (No.20110119-1-3).

References

- Ayadi W, Allaya N, Frikha H, et al (2014). Identification of a novel methylated gene in nasopharyngeal carcinoma: TTC40. *Biomed Res Int*, 2014, 691742.
- Ayadi W, Karray-Hakim H, Khabir A, et al (2008). Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. *Anticancer Res*, 28, 2161-7.

- Ayan I, Kaytan E, Ayan N (2003). Childhood nasopharyngeal carcinoma: from biology to treatment. *Lancet Oncol*, 4, 13-21.
- Baylin SB, Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. *Trends Genet*, 16, 168-74.
- Belinsky SA, Nikula KJ, Palmisano WA, et al (1998). Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. *Proc Natl Acad Sci U S A*, 95, 11891-6.
- Bruce JP, Yip K, Bratman SV, et al (2015). Nasopharyngeal Cancer: Molecular Landscape. J Clin Oncol, **33**, 3346-55**100.0**
- Challouf S, Ziadi S, Zaghdoudi R, et al (2012). Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. *Clin Chim Acta*, **413**, 795-802. **75.0**
- Chang HW, Chan A, Kwong DL, et al (2003a). Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient. *Clin Cancer***50.0** *Res*, **9**, 1033-8.
- Chang HW, Chan A, Kwong DL, et al (2003b). Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. *Int J Cancer*, **105**, 851-5.
- Chen F, Mo Y, Ding H, et al (2011). Frequent epigenetic inactivation of Myocardin in human nasopharyngeal carcinoma. *Head Neck*, **33**, 54-9.
- Chen T, Long B, Ren G, et al (2015). Protocadherin20 acts as a tumor suppressor gene: epigenetic inactivation in nasopharyngeal carcinoma. J Cell Biochem, 116, 1766-75.
- Cheung CC, Chung GT, Lun SW, et al (2014). miR-31 is consistently inactivated in EBV-associated nasopharyngeal carcinoma and contributes to its tumorigenesis. *Mol Cancer*, **13**, 184.
- Cheung HW, Ching YP, Nicholls JM, et al (2005). Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. *Mol Carcinog*, **43**, 237-45.
- Choi GC, Li J, Wang Y, et al (2014). The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. *Mol Cancer Res*, **12**, 228-38.
- Chow LS, Lo KW, Kwong J, et al (2004). RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. *Int J Cancer*, **109**, 839-47.
- Dai W, Cheung AK, Ko JM, et al (2015). Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. *Cancer Med*.
- Delpu Y, Cordelier P, Cho WC, et al (2013). DNA methylation and cancer diagnosis. *Int J Mol Sci*, **14**, 15029-58.
- Du C, Huang T, Sun D, et al (2011). CDH4 as a novel putative tumor suppressor gene epigenetically silenced by promoter hypermethylation in nasopharyngeal carcinoma. *Cancer Lett*, **309**, 54-61.
- Esteller M (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat Rev Genet*, **8**, 286-98.
- Fendri A, Khabir A, Hadri-Guiga B, et al (2010). Epigenetic alteration of the Wnt inhibitory factor-1 promoter is common and occurs in advanced stage of Tunisian nasopharyngeal carcinoma. *Cancer Invest*, 28, 896-903.
- Fendri A, Masmoudi A, Khabir A, et al (2009). Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. *Cancer Biol Ther*, 8, 444-51.

He D, Zeng Q, Ren G, et al (2012). Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter

56

0

Wei Jiang et al

methylation in nasopharyngeal carcinoma. *Eur J Cancer Prev*, **21**, 569-75.

- Heng DM, Wee J, Fong KW, et al (1999). Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. *Cancer*, **86**, 1912-20.
- Hong MH, Mai HQ, Min HQ, et al (2000). A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. *Cancer*, **89**, 242-7.
- Hutajulu SH, Indrasari SR, Indrawati LP, et al (2011). Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. *Mol Cancer*, **10**, 48.
- Jeannel D, Bouvier G, Hubert A (1999). Nasopharyngeal carcinoma: An epidemiological approach to carcinogenesis. *Cancer Surveys*, **33**, 125-55.
- Jiang W, Li YQ, Liu N, et al (2014). 5-Azacytidine enhances the radiosensitivity of CNE2 and SUNE1 cells in vitro and in vivo possibly by altering DNA methylation. *PLoS One*, 9, 93273.
- Jiang W, Liu N, Chen XZ, et al (2015). Genome-wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma. *Mol Cancer Ther.*
- Jones PA (1996). DNA methylation errors and cancer. Cancer Res, 56, 2463-7.
- Koga T, Takeshita M, Yano T, et al (2011). CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. *Int J Cancer*, **128**, 1009-17.
- Kwong J, Lo KW, Chow LS, et al (2005a). Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. *Int J Cancer*, **113**, 386-92.
- Kwong J, Lo KW, Chow LS, et al (2005b). Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. *Neoplasia*, 7, 67-74.
- Kwong J, Lo KW, To KF, et al (2002). Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. *Clin Cancer Res*, **8**, 131-7.
- Lee KY, Geng H, Ng KM, et al (2008). Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. *Oncogene*, 27, 5267-76.
- Li HP, Huang HY, Lai YR, et al (2014a). Silencing of miRNA-148a by hypermethylation activates the integrinmediated signaling pathway in nasopharyngeal carcinoma. *Oncotarget*, 5, 7610-24.
- Li J, Gong P, Lyu X, et al (2014b). Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker. *Oncol Rep*, **31**, 2206-12.
- Li L, Tao Q, Jin H, et al (2010). The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. *Clin Cancer Res*, **16**, 2949-58.
- Li L, Ying J, Tong X, et al (2014c). Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting beta-catenin and AKT signaling but frequently methylated in common carcinomas. *Cell Mol Life Sci*, **71**, 2179-92.
- Li L, Zhang Y, Fan Y, et al (2015a). Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. *Epigenomics*, **7**, 155-73.
- Li LL, Shu XS, Wang ZH, et al (2011a). Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. *Chin J Cancer*, **30**, 231-9.
- Li W, Li X, Wang W, et al (2011b). NOR1 is an HSF1- and
- 8064 Asian Pacific Journal of Cancer Prevention, Vol 16, 2015

NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma. *Carcinogenesis*, **32**, 1305-14.

- Li YQ, Ren XY, He QM, et al (2015b). MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. *Cell Death Dis*, **6**, 1618.
- Lin YC, You L, Xu Z, et al (2006). Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. *Biochem Biophys Res Commun*, **341**, 635-40.
- Liu H, Zhang L, Niu Z, et al (2008). Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells. *BMC Cancer*, **8**, 253.
- Liu XQ, Chen HK, Zhang XS, et al (2003). Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. *Int J Cancer*, **106**, 60-5.
- Lo KW, Cheung ST, Leung SF, et al (1996). Hypermethylation of the p16 gene in nasopharyngeal carcinoma. *Cancer Res*, **56**, 2721-5.
- Lo KW, Huang DP (2002). Genetic and epigenetic changes in nasopharyngeal carcinoma. *Semin Cancer Biol*, **12**, 451-62.
- Lo KW, Kwong J, Hui AB, et al (2001). High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. *Cancer Res*, **61**, 3877-81.
- Lo KW, To KF, Huang DP (2004). Focus on nasopharyngeal carcinoma. *Cancer Cell*, **5**, 423-8.
- Lo KW, Tsang YS, Kwong J, et al (2002). Promoter hypermethylation of the *EDNRB* gene in nasopharyngeal carcinoma. *Int J Cancer*, **98**, 651-5.
- Loyo M, Brait M, Kim MS, et al (2011). A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. *Int J Cancer*, **128**, 1393-403.
- Lujambio A, Calin GA, Villanueva A, et al (2008). A microRNA DNA methylation signature for human cancer metastasis. *Proc Natl Acad Sci U S A*, **105**, 13556-61.
- Luo FY, Xiao S, Liu ZH, et al (2015). Kank1 reexpression induced by 5-Aza-2'-deoxycytidine suppresses nasopharyngeal carcinoma cell proliferation and promotes apoptosis. *Int J Clin Exp Pathol*, 8, 1658-65.
- McDermott AL, Dutt SN, Watkinson JC (2001). The aetiology of nasopharyngeal carcinoma. *Clin Otolaryngol Allied Sci*, 26, 82-92.
- Mittag F, Kuester D, Vieth M, et al (2006). DAPK promotor methylation is an early event in colorectal carcinogenesis. *Cancer Lett*, **240**, 69-75.
- Mo Y, Midorikawa K, Zhang Z, et al (2012). Promoter hypermethylation of Ras-related GTPase gene RRAD inactivates a tumor suppressor function in nasopharyngeal carcinoma. *Cancer Lett*, **323**, 147-54.
- Nawaz I, Hu LF, Du ZM, et al (2015a). Integrin alpha9 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma. *Oncotarget*, **6**, 31493-507.
- Nawaz I, Moumad K, Martorelli D, et al (2015b). Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay. *Clin Epigenetics*, 7, 89.
- Peng D, Ren CP, Yi HM, et al (2006). Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai), 38, 349-55.
- Ramos EA, Camargo AA, Braun K, et al (2010). Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. *BMC Cancer*, **10**, 23.
- Ran Y, Wu S, You Y (2011). Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. J Biochem, 149, 49-54.
- Razak AR, Siu LL, Liu FF, et al (2010). Nasopharyngeal

carcinoma: the next challenges. Eur J Cancer, 46, 1967-78.

- Seng TJ, Low JS, Li H, et al (2007). The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. *Oncogene*, **26**, 934-44.
- Shu XS, Li L, Ji M, et al (2013). FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. *Carcinogenesis*, **34**, 1984-93.
- Sun D, Zhang Z, Van do N, et al (2007). Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. *Oral Oncol*, 43, 82-7.
- Sung FL, Cui Y, Hui EP, et al (2014). Silencing of hypoxiainducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma. Am J Cancer Res, 4, 789-800.
- Tao Q, Chan AT (2007). Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. *Expert Rev Mol Med*, **9**, 1-24.
- Tian F, Yip SP, Kwong DL, et al (2013). Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. *Cancer Epidemiol*, **37**, 708-13.
- Tong JH, Ng DC, Chau SL, et al (2010). Putative tumoursuppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. *BMC Cancer*, **10**, 253.
- Tong JH, Tsang RK, Lo KW, et al (2002). Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. *Clin Cancer Res*, **8**, 2612-9.
- Tsao SW, Liu Y, Wang X, et al (2003). The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. *Eur J Cancer*, **39**, 524-31.
- Wang S, Xiao X, Zhou X, et al (2010). TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. *BMC Cancer*, **10**, 617.
- Wang S, Zhang R, Claret FX, et al (2014). Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. *Mol Cancer Ther*, 13, 3163-74.
- Wei WI, Sham JS (2005). Nasopharyngeal carcinoma. Lancet, 365, 2041-54.
- Wong AM, Kong KL, Chen L, et al (2013). Characterization of CACNA2D3 as a putative tumor suppressor gene in the development and progression of nasopharyngeal carcinoma. *Int J Cancer*, **133**, 2284-95.
- Wong TS, Chang HW, Tang KC, et al (2002). High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. *Clin Cancer Res*, **8**, 433-7.
- Wong TS, Kwong DL, Sham JS, et al (2003a). Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma. *Clin Cancer Res*, 9, 3042-6.
- Wong TS, Kwong DL, Sham JS, et al (2004). Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. *Clin Cancer Res*, **10**, 2401-6.
- Wong TS, Tang KC, Kwong DL, et al (2003b). Differential gene methylation in undifferentiated nasopharyngeal carcinoma. *Int J Oncol*, 22, 869-74.
- Xiao X, Zhao W, Tian F, et al (2014). Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human

- nasopharyngeal carcinoma. *Tumour Biol*, **35**, 3755-63. Yanatatsaneejit *P*, Chalermchai T, Kerekhanjanarong V, et al (2008). Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma. *Oral Oncol*, **44**, 400-6.
- Yang X, Dai W, Kwong DL, et al (2015). Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. *Int J Cancer*, 136, 127-35.
- Yang Z, Lan H, Chen X, et al (2014). Molecular alterations of the WWOX gene in nasopharyngeal carcinoma. *Neoplasma*, 61, 170-6.
- Yi B, Tan SX, Tang CE, et al (2009). Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. *J Cell Biochem*, **106**, 858-66.
- Yi HM, Li H, Peng D, et al (2006). Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. *Oncol Res*, **16**, 261-72.
- Ying J, Li H, Seng TJ, et al (2006). Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. *Oncogene*, 25, 1070-80.
- Ying J, Srivastava G, Hsieh WS, et al (2005). The stressresponsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. *Clin Cancer Res*, **11**, 6442-9.
- You Y, Ma L, You M, et al (2010). TSLC1 gene silencing in cutaneous melanoma. *Melanoma Res*, **20**, 179-83.
- You Y, Yang W, Qin X, et al (2015). ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. *Cell Oncol*, **38**, 205-14.
- You Y, Yang W, Wang Z, et al (2013). Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. *Cell Oncol*, **36**, 323-31.
- Zhang H, Feng X, Liu W, et al (2011). Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. *J Cell Biochem*, **112**, 1832-43.
- Zhang S, Li S, Gao JL (2013). Promoter methylation status of the tumor suppressor gene SOX11 is associated with cell growth and invasion in nasopharyngeal carcinoma. *Cancer Cell Int*, 13, 109.
- Zhou W, Feng X, Li H, et al (2009). Inactivation of LARS2, located at the commonly deleted region 3p21.3, by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. *Acta Biochim Biophys Sin*, **41**, 54-62.